Resurrection of PARP Inhibitors in Breast Cancer

View More View Less
  • a Breast Medicine Service, and Clinical Genetics Service, Memorial Sloan Kettering Cancer Center, New York, New York.
Restricted access

PARP enzymes are essential for DNA damage repair. Cancers with defective homologous recombination DNA repair, such has BRCA1- and BRCA2-mutated breast cancers, are targets for PARP inhibitors (PARPi) through the exploitation of synthetic lethality. A number of PARPi are currently undergoing clinical evaluation in breast cancer, with olaparib and talazoparib having demonstrated superior efficacy compared with standard chemotherapy in advanced germline BRCA-mutated cancer. This review describes the biological rationale for PARPi and presents the accumulating data on PARPi use in breast cancer.

Correspondence: Mark E. Robson, MD, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065. Email: robsonm@mskcc.org
  • 1.

    Hoeijmakers JH. Genome maintenance mechanisms for preventing cancer. Nature 2001;411:366374.

  • 2.

    Hoeijmakers JH. DNA damage, aging, and cancer. N Engl J Med 2009;361:14751485.

  • 3.

    Lord CJ, Ashworth A. PARP inhibitors: synthetic lethality in the clinic. Science 2017;355:11521158.

  • 4.

    Pommier Y, O'Connor MJ, de Bono J. Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action. Sci Transl Med 2016;8:362ps17.

    • Search Google Scholar
    • Export Citation
  • 5.

    Bryant HE, Schultz N, Thomas HD. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005;434:913917.

    • Search Google Scholar
    • Export Citation
  • 6.

    Farmer H, McCabe N, Lord CJ. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005;434:917921.

  • 7.

    De Vos M, Schreiber V, Dantzer F. The diverse roles and clinical relevance of PARPs in DNA damage repair: current state of the art. Biochem Pharmacol 2012;84:137146.

    • Search Google Scholar
    • Export Citation
  • 8.

    Arun B, Akar U, Gutierrez-Barrera AM. The PARP inhibitor AZD2281 (Olaparib) induces autophagy/mitophagy in BRCA1 and BRCA2 mutant breast cancer cells. Int J Oncol 2015;47:262268.

    • Search Google Scholar
    • Export Citation
  • 9.

    Murai J, Pommier Y. Classification of PARP inhibitors based on PARP trapping and catalytic inhibition, and rationale for combinations with topoisomerase I inhibitors and alkylating agents. In: Curtin N, Sharma R, eds. PARP Inhibitors for Cancer Therapy. New York, NY: Humana Press; 2015:261274.

    • Search Google Scholar
    • Export Citation
  • 10.

    Fong PC, Boss DS, Yap TA. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009;361:123134.

  • 11.

    Tutt A, Robson M, Garber JE. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 2010;376:235244.

    • Search Google Scholar
    • Export Citation
  • 12.

    Kaufman B, Shapira-Frommer R, Schmutzler RK. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol 2015;33:244250.

    • Search Google Scholar
    • Export Citation
  • 13.

    Gelmon KA, Tischkowitz M, Mackay H. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol 2011;12:852861.

    • Search Google Scholar
    • Export Citation
  • 14.

    O'Shaughnessy J, Osborne C, Pippen JE. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med 2011;364:205214.

    • Search Google Scholar
    • Export Citation
  • 15.

    O'Shaughnessy J, Schwartzberg L, Danso MA. Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer. J Clin Oncol 2014;32:38403847.

    • Search Google Scholar
    • Export Citation
  • 16.

    Patel AG, De Lorenzo SB, Flatten KS. Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro. Clin Cancer Res 2012;18:16551662.

  • 17.

    Liu X, Shi Y, Maag DX. Iniparib nonselectively modifies cysteine-containing proteins in tumor cells and is not a bona fide PARP inhibitor. Clin Cancer Res 2012;18:510523.

    • Search Google Scholar
    • Export Citation
  • 18.

    Kaye SB, Lubinski J, Matulonis U. Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. J Clin Oncol 2012;30:372379.

    • Search Google Scholar
    • Export Citation
  • 19.

    Ledermann J, Harter P, Gourley C. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med 2012;366:13821392.

    • Search Google Scholar
    • Export Citation
  • 20.

    Robson M, Im SA, Senkus E. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med 2017;377:523533.

  • 21.

    de Bono J, Ramanathan RK, Mina L. Phase I, dose-escalation, two-part trial of the PARP Inhibitor talazoparib in patients with advanced germline BRCA1/2 mutations and selected sporadic cancers. Cancer Discov 2017;7:620629.

    • Search Google Scholar
    • Export Citation
  • 22.

    Turner NC, Telli ML, Rugo HS. Final results of a phase 2 study of talazoparib (TALA) following platinum or multiple cytotoxic regimens in advanced breast cancer patients (pts) with germline BRCA1/2 mutations (ABRAZO) [abstract]. J Clin Oncol 2017;35(15 Suppl):Abstract 1007.

    • Search Google Scholar
    • Export Citation
  • 23.

    Litton J, Rugo HS, Ettl J. EMBRACA: a phase 3 trial comparing talazoparib, an oral PARP inhibitor, to physician's choice of therapy in patients with advanced breast cancer and a germline BRCA mutation. Presented at the 2017 San Antonio Breast Cancer Symposium; December 5–9, 2017; San Antonio, Texas. Abstract GS6-07.

    • Search Google Scholar
    • Export Citation
  • 24.

    Puhalla S, Beumer JH, Pahuja S. Final results of a phase 1 study of single-agent veliparib (V) in patients (pts) with either BRCA1/2-mutated cancer (BRCA+), platinum-refractory ovarian, or basal-like breast cancer (BRCA-wt) [abstract]. J Clin Oncol 2014;32(Suppl):Abstract 2570.

    • Search Google Scholar
    • Export Citation
  • 25.

    Somlo G, Frankel PH, Arun BK. Efficacy of the PARP inhibitor veliparib with carboplatin or as a single agent in patients with germline BRCA1- or BRCA2-associated metastatic breast cancer: California Cancer Consortium Trial NCT01149083. Clin Cancer Res 2017;23:40664076.

    • Search Google Scholar
    • Export Citation
  • 26.

    Han HS, Sook DV, Robson ME. Efficacy and tolerability of veliparib (V; ABT-888) in combination with carboplatin (C) and paclitaxel (P) vs placebo (Plc)+C/P in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer: a randomized, phase 2 study [abstract]. Presented at the 2016 San Antonio Breast Cancer Symposium; December 6–10, 2016; San Antonio, Texas. Abstract S2-05

    • Search Google Scholar
    • Export Citation
  • 27.

    Mirza MR, Monk BJ, Herrstedt J. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med 2016;375:21542164.

    • Search Google Scholar
    • Export Citation
  • 28.

    Rugo HS, Olopade OI, DeMichele A. Adaptive randomization of veliparib–carboplatin treatment in breast cancer. N Engl J Med 2016;375:2334.

  • 29.

    Loibl S, O'Shaughnessy J, Untch M. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. Lancet Oncol 2018;19:497509.

    • Search Google Scholar
    • Export Citation
  • 30.

    Litton JK, Scoggins M, Ramirez DL. A feasibility study of neoadjuvant talazoparib for operable breast cancer patients with a germline BRCA mutation demonstrates marked activity. NPJ Breast Cancer 2017;3:49.

    • Search Google Scholar
    • Export Citation
  • 31.

    Khan OA, Gore M, Lorigan P. A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours. Br J Cancer 2011;104:750755.

    • Search Google Scholar
    • Export Citation
  • 32.

    Rajan A, Carter CA, Kelly RJ. A phase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumors. Clin Cancer Res 2012;18:23442351.

    • Search Google Scholar
    • Export Citation
  • 33.

    Balmana J, Tung NM, Isakoff SJ. Phase I trial of olaparib in combination with cisplatin for the treatment of patients with advanced breast, ovarian and other solid tumors. Ann Oncol 2014;25:16561663.

    • Search Google Scholar
    • Export Citation
  • 34.

    Le DT, Uram JN, Wang H. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 2015;372:25092520.

  • 35.

    Domchek SM, Postel-Vinay S, Bang YJ. An open-label, multitumor, phase II basket study of olaparib and durvalumab (MEDIOLA): results in germline BRCA-mutated (gBRCAm) HER2-negative metastatic breast cancer (MBC) [abstract]. Presented at the San Antonio Breast Cancer Symposium; December 5–9, 2017; San Antonio, Texas. Abstract PD6-11.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 2336 675 54
PDF Downloads 997 305 35
EPUB Downloads 0 0 0